Tamio Teramoto

Summary

Affiliation: Teikyo University
Country: Japan

Publications

  1. ncbi request reprint Review of efficacy of rosuvastatin 5 mg
    T Teramoto
    Teikyo University School of Medicine, Tokyo, Japan
    Int J Clin Pract 59:92-101. 2005
  2. ncbi request reprint Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Japan
    J Atheroscler Thromb 16:654-61. 2009
  3. doi request reprint Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
    Tamio Teramoto
    Teikyo Academic Research Center, Teikyo University, 2 11 1, Kaga, Itabashi ku, Tokyo 173 8606, Japan
    Cardiovasc Diabetol 12:163. 2013
  4. doi request reprint Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia
    Tamio Teramoto
    Teikyo University School of Medicine, Tokyo, Japan
    Atherosclerosis 230:52-60. 2013
  5. pmc Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA study
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Hypertens Res 35:1136-44. 2012
  6. doi request reprint Pitavastatin: clinical effects from the LIVES Study
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Kaga 2 11 1, Itabashi ku, Tokyo 173 8605, Japan
    Atheroscler Suppl 12:285-8. 2011
  7. pmc Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Cardiovasc Diabetol 11:29. 2012
  8. doi request reprint The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C
    Tamio Teramoto
    Teikyo University School of Medicine, Department of Internal Medicine, 2 11 1 Kaga Itabashi ku, Tokyo 173 8605, Japan
    Expert Opin Pharmacother 13:859-65. 2012
  9. ncbi request reprint APPROACH-J study: design, rationale, and baseline data of the affirmation primary prevention with pravastatin in reduction of occlusive atherosclerotic complications in hypercholesterolemia--Japan study
    Tamio Teramoto
    Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 18:1054-61. 2011
  10. ncbi request reprint Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Circ J 72:1569-75. 2008

Detail Information

Publications82

  1. ncbi request reprint Review of efficacy of rosuvastatin 5 mg
    T Teramoto
    Teikyo University School of Medicine, Tokyo, Japan
    Int J Clin Pract 59:92-101. 2005
    ..01 vs. atorvastatin 10 mg). These results demonstrate that rosuvastatin 5 mg produces favourable effects on the lipid profile and helps more patients achieve LDL-C goals than comparator statins...
  2. ncbi request reprint Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Japan
    J Atheroscler Thromb 16:654-61. 2009
    ..Statins have been known to have a potent HDL-C-elevating effect in addition to low-density lipoprotein cholesterol (LDL-C)-lowering effects...
  3. doi request reprint Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
    Tamio Teramoto
    Teikyo Academic Research Center, Teikyo University, 2 11 1, Kaga, Itabashi ku, Tokyo 173 8606, Japan
    Cardiovasc Diabetol 12:163. 2013
    ..In this study, we examined the safety, including the risk of gallstone formation, and the efficacy of long-term combination therapy with bezafibrate and ezetimibe for treating dyslipidemia...
  4. doi request reprint Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia
    Tamio Teramoto
    Teikyo University School of Medicine, Tokyo, Japan
    Atherosclerosis 230:52-60. 2013
    ..This study evaluated the effects of anacetrapib (ANA) on lipids and safety when administered as monotherapy or in combination with atorvastatin (ATV) in Japanese patients with dyslipidemia...
  5. pmc Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA study
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Hypertens Res 35:1136-44. 2012
    ....
  6. doi request reprint Pitavastatin: clinical effects from the LIVES Study
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Kaga 2 11 1, Itabashi ku, Tokyo 173 8605, Japan
    Atheroscler Suppl 12:285-8. 2011
    ....
  7. pmc Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Cardiovasc Diabetol 11:29. 2012
    ..We investigated glycemic control, relationship between lipid metabolism and HbA1c, and safety in diabetic patients treated with bezafibrate...
  8. doi request reprint The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C
    Tamio Teramoto
    Teikyo University School of Medicine, Department of Internal Medicine, 2 11 1 Kaga Itabashi ku, Tokyo 173 8605, Japan
    Expert Opin Pharmacother 13:859-65. 2012
    ..This review summarizes and evaluates new insights into pitavastatin, from clinical trials since 2010...
  9. ncbi request reprint APPROACH-J study: design, rationale, and baseline data of the affirmation primary prevention with pravastatin in reduction of occlusive atherosclerotic complications in hypercholesterolemia--Japan study
    Tamio Teramoto
    Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 18:1054-61. 2011
    ....
  10. ncbi request reprint Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Circ J 72:1569-75. 2008
    ..A simple and practical risk prediction tool for coronary heart disease (CHD) to determine the specific risk level in each patient that fits the true clinical practice setting is needed and would be valuable in Japan...
  11. ncbi request reprint Postprandial hyperlipidemia and atherosclerosis
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Curr Atheroscler Rep 9:169-70. 2007
  12. ncbi request reprint Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus
    Tamio Teramoto
    Department of Internal Medicine, School of Medicine, Teikyo University, Kaga, Tokyo, Japan
    J Atheroscler Thromb 14:86-93. 2007
    ..The effects of pioglitazone hydrochloride monotherapy on abnormal lipid control were evaluated in Japanese patients with type 2 diabetes mellitus, comparing with glibenclamide monotherapy...
  13. doi request reprint New evidence on pitavastatin: efficacy and safety in clinical studies
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Expert Opin Pharmacother 11:817-28. 2010
    ..Many clinical trials of pitavastatin have been done since its launch. New insights on pitavastatin from these trials are summarized and evaluated...
  14. doi request reprint Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events
    Tamio Teramoto
    Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Am Heart J 159:361-369.e4. 2010
    ..Prevention of atherosclerotic disease has become an important public health priority in Japan due to the aging of the population and changes in diet and lifestyle factors...
  15. ncbi request reprint Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 17:879-87. 2010
    ..To evaluate the relationship between low-density lipoprotein cholesterol (LDL-C) change and reduction of cardiovascular disease in the Management of Elevated cholesterol in the primary prevention Group of Adult Japanese (MEGA) study...
  16. doi request reprint OMEGA study: design, baseline data, metabolic syndrome prevalence in a large-scale observational study of hypertensive patients: The Olmesartan Mega Study to Determine the Relationship between Cardiovascular Endpoints and Blood Pressure Goal Achievement s
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, 2 11 1 Kaga, Itabashiku, Tokyo 173 8605, Japan
    Hypertens Res 31:2011-7. 2008
    ..The complete follow-up data from the OMEGA study will provide much-needed information to guide treatment in patients with hypertension and the metabolic syndrome. (Hypertens Res 2008; 31: 2011-2017)...
  17. ncbi request reprint Efficacy of raising high-density lipoprotein cholesterol for prevention of coronary heart disease
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, 2 11 1 Kaga Itabashi ku, Tokyo 173 8605, Japan
    Curr Atheroscler Rep 4:327-8. 2002
  18. pmc Sodium intake in men and potassium intake in women determine the prevalence of metabolic syndrome in Japanese hypertensive patients: OMEGA Study
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Hypertens Res 34:957-62. 2011
    ..Sodium and potassium intake affect MS prevalence. Dietary changes are warranted within hypertension treatment strategies...
  19. doi request reprint Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (
    Naoko Tajima
    Department of Internal Medicine, Jikei University School of Medicine 3 25 8, Nishi Shimbashi, Minato ku, 105 8461 Tokyo, Japan
    Atherosclerosis 199:455-62. 2008
    ..In conclusion, pravastatin reduces the risk of CVD in subjects with hypercholesterolemia and abnormal fasting glucose in the primary prevention setting in Japan...
  20. ncbi request reprint The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia
    Toshitsugu Ishikawa
    Occupational Health Department, Sony Corporation, Tokyo, Japan
    Circ J 72:1576-82. 2008
    ..The present analysis determined the risk factors for CHD in the MEGA Study, a large primary prevention trial with pravastatin in Japanese with hypercholesterolemia...
  21. ncbi request reprint Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison
    Yasushi Saito
    Second Department of Internal Medicine, School of Medicine, Chiba University, Chiba, Japan
    Arzneimittelforschung 52:251-5. 2002
    ..It also significantly decreased the serum levels of triglycerides (TG) within this dose range. There was no dose-dependence of the incidence of adverse reactions to pitavastatin...
  22. doi request reprint The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study
    Teruhiko Matsushima
    Faculty of Human Life Science, Jissen Women s University, Tokyo, Japan
    J Cardiovasc Pharmacol Ther 17:153-8. 2012
    ..These results indicate that low-dose pravastatin provides a substantial beneficial effect for the prevention of CVD in Japanese patients with MetSyn without known CVD, a population at proportionally high risk in primary prevention...
  23. doi request reprint Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study)
    Noriaki Nakaya
    Nakaya Clinic, Tokyo, Japan
    Drugs Aging 28:681-92. 2011
    ..Limited data are available regarding the relationship between age and the effect of HMG-CoA reductase inhibitor (statin) treatment...
  24. ncbi request reprint Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome
    Ryouta Maeba
    Department of Biochemistry, Teikyo University School of Medicine, Tokyo, Japan
    J Nutr Sci Vitaminol (Tokyo) 54:196-202. 2008
    ....
  25. doi request reprint Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study)
    Kyoichi Mizuno
    Department of Internal Medicine, Nippon Medical School, 1 1 5, Sendagi, Bunkyo ku, Tokyo, 113 8603, Japan
    Circulation 117:494-502. 2008
    ..We conducted an exploratory analysis of the effect of diet plus pravastatin therapy on the primary prevention of cardiovascular events in women with data from a large-scale primary prevention trial with pravastatin...
  26. ncbi request reprint Scavenger receptor type BI potentiates reverse cholesterol transport system by removing cholesterol ester from HDL
    Makoto Kinoshita
    Department of Internal Medicine, Teikyo University School of Medicine, 2 11 1 Kaga, Itabashi, Tokyo 173 8605, Japan
    Atherosclerosis 173:197-202. 2004
    ..These results indicate that SR-BI reduces the cholesterol content and size of the CE-rich HDL from CETP deficiency, which ultimately activate reverse cholesterol transport system...
  27. ncbi request reprint Gentisic acid, an aspirin metabolite, inhibits oxidation of low-density lipoprotein and the formation of cholesterol ester hydroperoxides in human plasma
    Keiko Ashidate
    Department of Internal Medicine, Kudanzaka Hospital, Tokyo, Japan
    Eur J Pharmacol 513:173-9. 2005
    ..Gentisic acid had a potent free radical scavenging activity with a minimal chelating effect. The potent antioxidant property of gentisic acid may partly account for the anti-atherogenic effects of aspirin...
  28. ncbi request reprint Isolation and characterization of apolipoprotein B48-containing lipoproteins with a monoclonal antibody against apolipoprotein B48
    Nakayuki Yoshimura
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 16:740-7. 2009
    ..In this study, we isolated apoB48-containing lipoproteins from lipoproteins with a density less than 1.019 g/mL using this anti-apoB48 monoclonal antibody (4C8)...
  29. ncbi request reprint Usefulness of LDL-C-related parameters to predict cardiovascular risk and effect of pravastatin in mild-to-moderate hypercholesterolemia
    Kyoichi Mizuno
    Department of Medicine, Nippon Medical School, Bunkyo ku, Tokyo, Japan
    J Atheroscler Thromb 19:176-85. 2012
    ....
  30. ncbi request reprint Physical activity in the Japan population: association with blood lipid levels and effects in reducing cardiovascular and all-cause mortality
    Shinji Koba
    Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 18:833-45. 2011
    ..38 to 14.65, p< 0.0001). While this confirms the importance of physical activity in preventing CVD mortality and all-cause mortality, the levels of physical activity are on a declining trend in Japan, particularly among the young...
  31. ncbi request reprint Increased serum apolipoprotein B48 concentration in patients with metabolic syndrome
    Makoto Kinoshita
    Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 16:517-22. 2009
    ..We hypothesized that fasting apo B48 levels may be increased in metabolic syndrome...
  32. ncbi request reprint Association of cholesteryl ester transfer protein activity and TaqIB polymorphism with lipoprotein variations in Japanese subjects
    Katsunori Ikewaki
    Department of Cardiology, Jikei University School of Medicine, Tokyo, Japan
    Metabolism 52:1564-70. 2003
    ..These data demonstrate that CETP activity is a significant determinant of HDL-C and LDL-C levels and that TaqIB CETP gene polymorphism affects CETP activity and HDL-C level in Japanese population examined...
  33. ncbi request reprint Determination of immuno-reactive rabbit apolipoprotein B-48 in serum by ELISA
    Makoto Kinoshita
    Department of Internal Medicine, Teikyo University School of Medicine, Itabashi, Tokyo, Japan
    Exp Anim 59:459-67. 2010
    ..This method for measuring apoB-48 using the monoclonal antibody is simple, reliable, and suitable for routine analyses...
  34. ncbi request reprint Adherence to preferable behavior for lipid control by high-risk dyslipidemic Japanese patients under pravastatin treatment: the APPROACH-J study
    Yasuhisa Kitagawa
    Department of Neurology, Tokai University Hachioji Hospital, Tokyo, Japan
    J Atheroscler Thromb 19:795-805. 2012
    ..We evaluated the impact of adherence to preferable behavior on serum lipid control assessed by a self-reported questionnaire in high-risk patients taking pravastatin for primary prevention of coronary artery disease...
  35. ncbi request reprint Enhanced susceptibility of LDL to oxidative modification in a CTX patient:- role of chenodeoxycholic acid in xanthoma formation
    Makoto Kinoshita
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 11:167-72. 2004
    ..This evidence suggests that the multiple xanthomas observed in CTX may be induced by increased oxidized LDL and the low activity of CETP, both of which are caused by a lack of CDCA...
  36. ncbi request reprint Critical promoter region for statin-induced human endothelial nitric oxide synthase (eNOS) transcription in EA.hy926 cells
    Yamato Mashimo
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 20:321-9. 2013
    ..We tried to identify other statin-responsive promoter regions...
  37. ncbi request reprint [Clinical significance of plasma total cholesterol, free cholesterol and esterified cholesterol levels]
    Masanari Taki
    Department of Internal Medicine, Teikyo University School of Medicine
    Nihon Rinsho 62:10-3. 2004
  38. ncbi request reprint Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study
    Kenjiro Kimura
    Department of Nephrology and Hypertension, Internal Medicine, St Marianna University School of Medicine, Kanagawa, Japan
    J Atheroscler Thromb 17:601-9. 2010
    ..In addition to the risk of progression to end-stage renal disease (ESRD), chronic kidney disease (CKD) is also known to be associated with an elevated risk of cardiovascular disease (CVD). Statins may improve renal function in CKD patients...
  39. ncbi request reprint A SNP of NPC1L1 affects cholesterol absorption in Japanese
    Tomomi Maeda
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 17:356-60. 2010
    ..The response of serum LDL-C levels to ezetimibe was reported to differe among NPC1L1 haplotypes.We analyzed NPC1L1 genotypes in Japanese and investigated differences in markers of cholesterol synthesis/absorption among the genotypes...
  40. ncbi request reprint Japanese dietary lifestyle and cardiovascular disease
    Norio Tada
    Division of Metabolism and Nutrition, Department of Internal Medicine, The Jikei University Graduate School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 18:723-34. 2011
    ....
  41. ncbi request reprint Plasmalogens in human serum positively correlate with high- density lipoprotein and decrease with aging
    Ryouta Maeba
    Department of Biochemistry, Teikyo University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 14:12-8. 2007
    ..The objective of the present study was to propose plasmalogens as a beneficial factor in human plasma by showing a highly positive correlation with high-density lipoprotein (HDL) and a significant reduction with aging...
  42. ncbi request reprint A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia
    Yasushi Saito
    The Second Department of Internal Medicine, School of Medicine, Chiba University, Chiba, Japan
    Atherosclerosis 162:373-9. 2002
    ..These results indicated that pitavastatin was more effective than pravastatin, and both drugs were well-tolerated in the treatment of hypercholesterolemia...
  43. doi request reprint Serum from methimazole-treated patients induces activation of aryl hydrocarbon receptor, a transcription factor that binds to dioxin-response elements
    Toshio Ishikawa
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Thyroid 22:769-77. 2012
    ..To investigate whether AhR-activating substances accumulate in patients with endocrine disorders, we tested serum samples for AhR-stimulating activity...
  44. ncbi request reprint [Dyslipidemia]
    Yamato Mashimo
    Department of Internal Medicine, Teikyo University School of Medicine
    Nihon Rinsho 70:852-6. 2012
    ..It is important to integrate and control these risk factors for the prevention of atherosclerosis as a real endpoint of diagnosis and treatment of dyslipidemia...
  45. ncbi request reprint Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia
    Chizuko Maruyama
    Department of Food and Nutrition, Japan Women s University, Tokyo, Japan
    J Atheroscler Thromb 10:186-91. 2003
    ..9 using mmol/L or 2.0 using mg/dL, while only 25% of the normal LDL group had ratios above the levels (p = 0.0013). A combined parameter, the TG/HDL-C ratio, is beneficial for assessing the presence of small LDL...
  46. ncbi request reprint Ascorbic acid augments cytotoxicity induced by oxidized low-density lipoprotein
    Keiko Ashidate
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Tokyo Teishin Hospital, Tokyo, Japan
    J Atheroscler Thromb 10:7-12. 2003
    ..These data suggest that ASA may act as a pro-oxidant under the condition of extensive LDL oxidation. To prevent oxidation stress, ASA would be better used together with lipid-soluble antioxidants for antioxidant therapies...
  47. ncbi request reprint Differences in serum phospholipid fatty acid compositions and estimated desaturase activities between Japanese men with and without metabolic syndrome
    Chizuko Maruyama
    Department of Food and Nutrition, Faculty of Home Economics, Japan Women s University, Tokyo, Japan
    J Atheroscler Thromb 15:306-13. 2008
    ..This study was designed to clarify differences in serum phospholipid fatty acid compositions and estimated desaturase activities between Japanese men with and without metabolic syndrome (MetS)...
  48. ncbi request reprint Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic
    Mutsuhiro Nakao
    Division of Psychosomatic Medicine, Teikyo University Hospital, Tokyo, Japan
    Psychiatry Clin Neurosci 60:605-10. 2006
    ..05) among the three groups during the intervention period. The use of SSRI may have beneficial effects on BDZ withdrawal without the worsening of mood states in cases without major depression...
  49. ncbi request reprint Doxazosin, an alpha1-adrenergic antihypertensive agent, decreases serum oxidized LDL
    M Kinoshita
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Am J Hypertens 14:267-70. 2001
    ....
  50. ncbi request reprint The effects of combination therapy with niceritrol and pravastatin on hyperlipidaemia
    M Kinoshita
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    J Int Med Res 30:271-81. 2002
    ..We conclude that when a single lipid-lowering drug fails to show therapeutic value, attempting combination therapy with a nicotinic acid preparation and a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) is worthwhile...
  51. ncbi request reprint Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease
    Toru Suzuki
    Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Clin Biochem 35:347-53. 2002
    ..To examine the diagnostic performance of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary heart disease...
  52. ncbi request reprint [Leading role of Framingham Heart Study in the epidemiology on cardiovascular diseases]
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine
    Nihon Rinsho 64:50-8. 2006
  53. ncbi request reprint Determination of apolipoprotein B-48 in serum by a sandwich ELISA
    Makoto Kinoshita
    Department of Internal Medicine, Teikyo University School of Medicine, Itabashi, Tokyo 173 8605 Japan
    Clin Chim Acta 351:115-20. 2005
    ..We have developed an assay for routine analysis to quantify apoB-48 in serum or plasma...
  54. doi request reprint A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects
    Takashi Miida
    Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Atherosclerosis 225:208-15. 2012
    ..In this study, we aimed to verify whether LDL-C levels determined by homogeneous assays [LDL-C (H)] agree with those determined by a beta-quantification method [LDL-C (BQ)] in fresh clinical samples...
  55. ncbi request reprint [Revision of Japanese guideline for prevention of CHD based on recent evidences]
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine
    Nihon Rinsho 60:899-907. 2002
    ..The new guideline is still on process...
  56. ncbi request reprint [Dislipidemia and steatohepatitis with visceral fat]
    Daijiro Yasuda
    Department of Internal Medicine, Teikyo University School of Medicine
    Nihon Rinsho 67:344-9. 2009
    ..Reduction of body weight and increase in physical activities are highly recommended in overweight patients to inhibit the development of metabolic syndrome, the dislipidemia and NASH...
  57. doi request reprint Usefulness of gram-stained sputum obtained just after administration of antimicrobial agents as the earliest therapeutic indicator for evaluating the effectiveness of empiric therapy in community-acquired pneumonia caused by pneumococcus or Moraxella cata
    Ryuichi Fujisaki
    Department of Internal Medicine, Teikyo University School of Medicine, Kaga 2 11 1, Itabashi ku, Tokyo, 173 8605, Japan
    J Infect Chemother 19:517-23. 2013
    ....
  58. ncbi request reprint [Role of HMG-CoA inhibitor (statin) in prevention of cerebral infarction]
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine
    Nihon Rinsho 64:736-43. 2006
  59. ncbi request reprint Synergically increased expression of CD36, CLA-1 and CD68, but not of SR-A and LOX-1, with the progression to foam cells from macrophages
    Kayo Tsukamoto
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 9:57-64. 2002
    ..We thus propose that CD36, CLA-1 and CD68, but not SR-A and LOX-1, may play crucial roles in the progression of macrophages to foam cells, which is a key step for the initiation of atherosclerosis...
  60. ncbi request reprint [New guideline for prevention of atherosclerotic diseases]
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine
    Nihon Rinsho 65:435-41. 2007
  61. ncbi request reprint [Cause of hypolipidemia: inflammation]
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine
    Nihon Rinsho 65:653-7. 2007
  62. doi request reprint Screening method for severe sleep-disordered breathing in hypertensive patients without daytime sleepiness
    Taiji Furukawa
    The Department of Medicine, Teikyo University School of Medicine, Itabashi ku, Tokyo, Japan
    J Cardiol 53:79-85. 2009
    ..1% and 64.5%, respectively. Daytime 30-min recording with a portable device for apnea detection during PWV recording is useful for screening of asymptomatic severe SDB in hypertensive patients...
  63. ncbi request reprint Dose-dependent effect of niceritrol on plasma lipoprotein-a
    T Teramoto
    First Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Scand J Clin Lab Invest 56:359-65. 1996
    ..The results suggest that the reduction of Lp(a) was dependent on the dose of niceritrol and on the pretreatment level of Lp(a). In conclusion, niceritrol is effective, in a dose-dependent manner, for reducing Lp(a) levels...
  64. ncbi request reprint Novel mutations in ABCA1 gene in Japanese patients with Tangier disease and familial high density lipoprotein deficiency with coronary heart disease
    W Huang
    Department of Internal Medicine, Fukuoka University School of Medicine, Nanakuma, Jonan ku, Fukuoka 810 0072, Japan
    Biochim Biophys Acta 1537:71-8. 2001
    ..These mutations were confirmed by restriction digestion analysis, and were not found in 141 control subjects. Our findings indicate that mutations in the ABCA1 gene are associated with TD as well as FHA...
  65. ncbi request reprint Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000
    Hidenori Arai
    Department of Geriatric Medicine, Kyoto University School of Medicine, 54 Kawahara cho, Shogoin, Sakuo ku, Kyoto 606 8507, Japan
    J Atheroscler Thromb 12:240-50. 2005
    ..Further study is necessary to elucidate the role of these gene polymorphisms in cardiovascular events...
  66. ncbi request reprint Serum lipid survey and its recent trend in the general Japanese population in 2000
    Hidenori Arai
    Department of Geriatric Medicine, Kyoto University School of Medicine, 54 Kawahara cho, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    J Atheroscler Thromb 12:98-106. 2005
    ..The present results will become the standard serum lipid level data for the Japanese people, and succeeding 10-year surveys will clarify the trends of lipid levels in this country...
  67. ncbi request reprint HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes
    Hirohito Sone
    Department of Internal Medicine Endocrinology Metabolism, Institute of Clinical Medicine, University of Tsukuba, 1 1 1 Tennodai, Tsukuba, 305 8575, Ibaraki, Japan
    Life Sci 71:2403-12. 2002
    ....
  68. ncbi request reprint [Medical care for hyperlipidemia]
    Tamio Teramoto
    Nihon Naika Gakkai Zasshi 95:1932-8. 2006
  69. ncbi request reprint Risk factors of atherosclerotic diseases. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerosis cardiovascular diseases for Japanese
    Tamio Teramoto
    Committee for Epidemiology and Clinical Management of Atherosclerosis, Japan
    J Atheroscler Thromb 14:267-77. 2007
  70. ncbi request reprint Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese
    Tamio Teramoto
    J Atheroscler Thromb 14:155-8. 2007
  71. ncbi request reprint Polymorphisms of apolipoprotein e and methylenetetrahydrofolate reductase in the Japanese population
    Hidenori Arai
    Department of Geriatric Medicine, Kyoto University Graduate School of Medicine, Japan
    J Atheroscler Thromb 14:167-71. 2007
    ..The aim of this study is to analyze the effect of apolipoprotein E (apo E) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms on serum lipid and homocysteine levels in the general Japanese population...
  72. ncbi request reprint Goals of dyslipidemia management
    Tamio Teramoto
    J Atheroscler Thromb 14:209-12. 2007
  73. ncbi request reprint Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese
    Tamio Teramoto
    Committee for Epidemiology and Clinical Management of Atherosclerosis, Japan
    J Atheroscler Thromb 14:45-50. 2007
  74. doi request reprint Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases
    Takamitsu Nakano
    JIMRO Laboratories, 351 1 Nishiyokote cho, Takasaki, Gunma 370 0021, Japan
    Clin Chim Acta 390:38-43. 2008
    ..ApoB-48 is a major apolipoprotein secreted by the small intestine and is the main constitutive apolipoprotein in chylomicrons (CM). In the past, presence of apoB-48 in human aortic atherosclerotic plaques has not been detected...
  75. ncbi request reprint Metabolic syndrome
    Tamio Teramoto
    Committee for Epidemiology and Clinical Management of Atherosclerosis
    J Atheroscler Thromb 15:1-5. 2008
  76. ncbi request reprint [Coronary artery disease in patients with diabetes mellitus and its treatment]
    Tamio Teramoto
    Nihon Naika Gakkai Zasshi 91:94-9. 2002
  77. ncbi request reprint Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults
    Yoshiya Hata
    J Atheroscler Thromb 9:1-27. 2002
    ..6) This part of the guideline gives only the diagnostic aspects of hyperlipidemias. The part of management and treatment will follow in the second section of the guideline that will be published in future...
  78. ncbi request reprint [Management of hyperlipidemia in elderly subjects]
    Tamio Teramoto
    Nihon Ronen Igakkai Zasshi 40:216-8. 2003
  79. ncbi request reprint Prevalence of metabolic syndrome in the general Japanese population in 2000
    Hidenori Arai
    Department of Geriatric Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
    J Atheroscler Thromb 13:202-8. 2006
    ..Intervention to reduce the incidence of metabolic syndrome in Japan is necessary to reduce the risk of cardiovascular disease...
  80. ncbi request reprint Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes
    Kenji Nagata
    First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan
    Atherosclerosis 163:39-47. 2002
    ..Our results suggest that Rho/Rho-kinase signaling is involved in the synthesis of TF in human monocytes and that inhibition of Rho/Rho-kinase may be useful for treating thrombogenicity in coronary artery disease...
  81. ncbi request reprint Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes
    Toshiyuki Ishibashi
    First Department of Internal Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960 1295, Japan
    Biochim Biophys Acta 1590:123-30. 2002
    ..Moreover, Rho-kinase inhibitors, Y-27632 and fasudil, suppressed the synthesis of PAI-1 in this culture system. We show that inhibition of Rho/Rho-kinase signaling downregulates the synthesis of PAI-1 in human monocytes...
  82. ncbi request reprint [Significance and management of hyperlipemia as a risk factor for the progression of arteriosclerosis]
    Tamio Teramoto
    Nihon Naika Gakkai Zasshi 94:416-22. 2005